415.98

0.35% 1.46

After Hours: 415.98

Idexx Laboratories Inc (IDXX)

Overview News Price History Option Chain Financials Why IDXX Down? Discussions Forecast Stock Split

Idexx Laboratories Inc stock is traded at $415.98, with a volume of 528.09K. It is up +0.35% in the last 24 hours and down -12.91% over the past month. Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.

Previous Close:

$414.52

Open:

$413.83

24h Volume:

528.09K

Relative Volume:

1.06

Market Cap:

$34.06B

Revenue:

$3.78B

Net Income/Loss:

$845.63M

P/E Ratio:

42.45

EPS:

9.8

Net Cash Flow:

$838.95M

1W Performance:

-7.11%

1M Performance:

-12.91%

6M Performance:

-13.45%

1Y Performance:

-3.10%

1-Day Range:

$412.31

$418.54

1-Week Range:

$404.74

$456.66

52-Week Range:

$404.74

$583.39

Idexx Laboratories Inc Stock (IDXX) Company Profile

Name

Idexx Laboratories Inc

Sector

Healthcare (1182)

Industry

Diagnostics & Research (57)

Phone

(207) 556-0300

Address

ONE IDEXX DRIVE, WESTBROOK, ME

Employee

11,000

Twitter

@idexx

Next Earnings Date

2024-10-31

Latest SEC Filings

IDXX's Discussions on Twitter

Idexx Laboratories Inc Stock (IDXX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-25-24	Initiated	BTIG Research	Buy
Jan-30-24	Downgrade	Piper Sandler	Overweight → Neutral
Dec-07-23	Initiated	Exane BNP Paribas	Outperform
Dec-04-23	Upgrade	Cleveland Research	Neutral → Buy
Aug-02-23	Downgrade	Atlantic Equities	Overweight → Neutral
Jul-25-22	Downgrade	Stifel	Buy → Hold
Jul-21-22	Upgrade	Goldman	Neutral → Buy
Jul-12-22	Initiated	Piper Sandler	Overweight
May-05-22	Downgrade	BofA Securities	Buy → Neutral
Feb-08-22	Initiated	Atlantic Equities	Overweight
Nov-18-21	Initiated	Morgan Stanley	Overweight
Aug-05-21	Resumed	Credit Suisse	Outperform
Jul-12-21	Downgrade	Guggenheim	Buy → Neutral
Feb-17-21	Initiated	Barclays	Overweight
Sep-09-19	Initiated	Goldman	Neutral
May-23-19	Initiated	Guggenheim	Buy
Nov-02-18	Reiterated	BofA/Merrill	Buy
May-07-18	Reiterated	Stifel	Buy
Jan-16-18	Initiated	Piper Jaffray	Overweight
Aug-23-17	Upgrade	BofA/Merrill	Neutral → Buy
Jul-28-17	Upgrade	CL King	Neutral → Buy
Feb-03-17	Downgrade	Feltl & Co.	Hold → Sell
Sep-29-16	Resumed	BofA/Merrill	Neutral
Aug-16-16	Reiterated	Stifel	Buy
Aug-03-16	Upgrade	Northcoast	Sell → Neutral
Jul-20-16	Reiterated	Canaccord Genuity	Buy
Apr-19-16	Reiterated	Canaccord Genuity	Buy
Apr-01-16	Initiated	CL King	Neutral
Mar-21-16	Reiterated	Stifel	Buy
Feb-04-16	Initiated	Credit Suisse	Outperform
Oct-29-15	Reiterated	Stifel	Buy
Aug-28-15	Downgrade	Raymond James	Outperform → Mkt Perform
Aug-13-15	Reiterated	Stifel	Buy
Jul-23-15	Reiterated	Canaccord Genuity	Buy

View All

Idexx Laboratories Inc Stock (IDXX) Latest News

09:53 AM

A Once-in-a-Decade Opportunity: 1 Super S&P 500 Stock Down 40% to Buy After Its Recent Pullback - The Motley Fool

09:53 AM

02:27 AM

Vanguard Group Inc's Strategic Acquisition of IDEXX Laboratories Shares - GuruFocus.com

02:27 AM

01:35 AM

IDEXX Laboratories' SWOT analysis: veterinary diagnostics leader faces market shifts - Investing.com

01:35 AM

Nov 04, 2024

IDEXX Laboratories (NASDAQ:IDXX) Receives "Neutral" Rating from Piper Sandler - MarketBeat

Nov 04, 2024

IDEXX Laboratories (NASDAQ:IDXX) Price Target Lowered to $481.00 at Barclays - MarketBeat

Nov 04, 2024

Robeco Institutional Asset Management B.V. Decreases Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) - MarketBeat

Nov 04, 2024

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Nov 04, 2024

IDEXX stock falls 10% on Q3 revenue miss, lowered guidance - MSN

Nov 04, 2024

Nov 03, 2024

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stake Reduced by New York State Common Retirement Fund - MarketBeat

Nov 03, 2024

Nov 02, 2024

IDEXX Laboratories (WBO:IDXX) Enterprise Value : €32,027 Mil (As of Nov. 02, 2024) - GuruFocus.com

Nov 02, 2024

IDEXX Laboratories (NASDAQ:IDXX) Posts Quarterly Earnings Results, Beats Estimates By $0.11 EPS - MarketBeat

Nov 02, 2024

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 02, 2024

Nov 01, 2024

Earnings call: IDEXX reports solid Q3 growth, revises full-year guidance - Investing.com Australia

Nov 01, 2024

Here’s Why Aristotle Focus Growth Strategy Sold IDEXX Laboratories (IDXX) - Insider Monkey

Nov 01, 2024

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stock Position Reduced by AustralianSuper Pty Ltd - MarketBeat

Nov 01, 2024